JP6091513B2 - 複素環化合物、前記化合物を含む薬物、これらの使用及びこれらの調製方法 - Google Patents
複素環化合物、前記化合物を含む薬物、これらの使用及びこれらの調製方法 Download PDFInfo
- Publication number
- JP6091513B2 JP6091513B2 JP2014539297A JP2014539297A JP6091513B2 JP 6091513 B2 JP6091513 B2 JP 6091513B2 JP 2014539297 A JP2014539297 A JP 2014539297A JP 2014539297 A JP2014539297 A JP 2014539297A JP 6091513 B2 JP6091513 B2 JP 6091513B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- compound
- phenyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c1nc(C(N=C(N)NBC*N(*C*F)*N(*)I)=O)c(N)nc1N Chemical compound *c1nc(C(N=C(N)NBC*N(*C*F)*N(*)I)=O)c(N)nc1N 0.000 description 4
- QUKHJXMFJJADLJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(CCc(cc1)ccc1C(N)=O)C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(CCc(cc1)ccc1C(N)=O)C#N)=O QUKHJXMFJJADLJ-UHFFFAOYSA-N 0.000 description 1
- LDXLICJWQBLYJN-UHFFFAOYSA-N CC(C)(C)OC(N/C(/NCC(CCc1ccccc1)(CC1)CCN1C(NCCN(C)C)=O)=N\C(c(nc1Cl)c(N)nc1NC)=O)=O Chemical compound CC(C)(C)OC(N/C(/NCC(CCc1ccccc1)(CC1)CCN1C(NCCN(C)C)=O)=N\C(c(nc1Cl)c(N)nc1NC)=O)=O LDXLICJWQBLYJN-UHFFFAOYSA-N 0.000 description 1
- ZFZGEXZIPWOIAE-UHFFFAOYSA-N CC(C)(C)OC(N1CCC(CCc2ccccc2)(CNC(NC(c2nc(Cl)c(N)nc2N)=O)=N)CC1)=O Chemical compound CC(C)(C)OC(N1CCC(CCc2ccccc2)(CNC(NC(c2nc(Cl)c(N)nc2N)=O)=N)CC1)=O ZFZGEXZIPWOIAE-UHFFFAOYSA-N 0.000 description 1
- YSDBJKNOEWSFGA-UHFFFAOYSA-N CC(N1CCN(C)CC1)=O Chemical compound CC(N1CCN(C)CC1)=O YSDBJKNOEWSFGA-UHFFFAOYSA-N 0.000 description 1
- WHTUWYBGTLLCKF-UHFFFAOYSA-N CC(NC1CCN(C)CC1)=O Chemical compound CC(NC1CCN(C)CC1)=O WHTUWYBGTLLCKF-UHFFFAOYSA-N 0.000 description 1
- NGEBDYZKTYWHRA-UHFFFAOYSA-N CC(NC1CC[N](C)(C)CC1)=O Chemical compound CC(NC1CC[N](C)(C)CC1)=O NGEBDYZKTYWHRA-UHFFFAOYSA-N 0.000 description 1
- WBPLCMQRJPGQHE-UHFFFAOYSA-N CC([N]1(C)CCN(C)CC1)=O Chemical compound CC([N]1(C)CCN(C)CC1)=O WBPLCMQRJPGQHE-UHFFFAOYSA-N 0.000 description 1
- VKXJKJLNGSBJTA-UHFFFAOYSA-N CN(C)CCCNC(N(CC1)CCC1(CN)c1ccccc1)=O Chemical compound CN(C)CCCNC(N(CC1)CCC1(CN)c1ccccc1)=O VKXJKJLNGSBJTA-UHFFFAOYSA-N 0.000 description 1
- XUDVRUCITLHGBH-UHFFFAOYSA-N CN(CC1)CCC1NC(N1CCC(CCc2ccccc2)(CN/C(/N)=N/C(c2nc(Cl)c(N)nc2N)=O)CC1)=O Chemical compound CN(CC1)CCC1NC(N1CCC(CCc2ccccc2)(CN/C(/N)=N/C(c2nc(Cl)c(N)nc2N)=O)CC1)=O XUDVRUCITLHGBH-UHFFFAOYSA-N 0.000 description 1
- KOOBYHRLTYIPTH-UHFFFAOYSA-N COC(c(nc1Cl)c(N)nc1N)=O Chemical compound COC(c(nc1Cl)c(N)nc1N)=O KOOBYHRLTYIPTH-UHFFFAOYSA-N 0.000 description 1
- BPXUIMFOWKBCMM-UHFFFAOYSA-N N/C(/NCC1(CCc2ccccc2)CCNCC1)=N\C(c1nc(Cl)c(N)nc1N)=O Chemical compound N/C(/NCC1(CCc2ccccc2)CCNCC1)=N\C(c1nc(Cl)c(N)nc1N)=O BPXUIMFOWKBCMM-UHFFFAOYSA-N 0.000 description 1
- OCSQJDAUOOHJEI-UHFFFAOYSA-N Nc(nc1N)c(C(O)=O)nc1Cl Chemical compound Nc(nc1N)c(C(O)=O)nc1Cl OCSQJDAUOOHJEI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11187553.0 | 2011-11-02 | ||
| EP11187553 | 2011-11-02 | ||
| PCT/EP2012/071352 WO2013064450A1 (en) | 2011-11-02 | 2012-10-29 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014534222A JP2014534222A (ja) | 2014-12-18 |
| JP2014534222A5 JP2014534222A5 (enExample) | 2015-12-17 |
| JP6091513B2 true JP6091513B2 (ja) | 2017-03-08 |
Family
ID=47073464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539297A Active JP6091513B2 (ja) | 2011-11-02 | 2012-10-29 | 複素環化合物、前記化合物を含む薬物、これらの使用及びこれらの調製方法 |
Country Status (34)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
| HRP20171614T1 (hr) * | 2011-11-02 | 2017-12-01 | Boehringer Ingelheim International Gmbh | Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju |
| CA2915633A1 (en) * | 2013-07-02 | 2015-01-08 | The California Institute For Biomedical Research | Compounds for treatment of cystic fibrosis |
| EP3019492B1 (en) * | 2013-07-08 | 2017-09-06 | Boehringer Ingelheim International GmbH | Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| JP6217866B2 (ja) * | 2014-10-24 | 2017-10-25 | 小野薬品工業株式会社 | Ｋｃｎｑ２〜５チャネル活性化剤 |
| WO2016112120A1 (en) * | 2015-01-07 | 2016-07-14 | The California Institute For Biomedical Research | Compounds for treatment of cystic fibrosis |
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| CA3192236A1 (en) | 2020-09-10 | 2022-03-17 | Tony Lahoutte | Antibody fragment against fap |
| CN112107580A (zh) * | 2020-09-29 | 2020-12-22 | 北京鑫开元医药科技有限公司 | 一种脾酪氨酸激酶抑制剂的制剂组合物及其制备方法 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| WO2024243025A1 (en) * | 2023-05-19 | 2024-11-28 | Ikena Oncology, Inc. | Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6812003A (enExample) | 1967-09-07 | 1969-03-11 | ||
| US3953476A (en) | 1971-12-27 | 1976-04-27 | Merck & Co., Inc. | 3-Amino-5-sulfonylbenzoic acids |
| CA2378181A1 (en) | 1999-07-19 | 2001-01-25 | Richard C. Boucher, Jr. | Conjugates of sodium channel blockers and methods of using the same |
| AU2001229501A1 (en) | 2000-01-24 | 2001-07-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of inducible nitric oxide synthase expression |
| KR20070059063A (ko) | 2004-08-18 | 2007-06-11 | 마이클 알 존슨. | 지방족 아미드 및 에스테르 피라지노일구아니딘 나트륨채널 차단제 |
| GB0526244D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| CA2658813A1 (en) * | 2006-07-24 | 2008-01-31 | International Stem Cell Corporation | Synthetic cornea from retinal stem cells |
| KR20100005730A (ko) * | 2007-05-07 | 2010-01-15 | 노파르티스 아게 | 유기 화합물 |
| EA017919B1 (ru) | 2007-12-10 | 2013-04-30 | Новартис Аг | Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов |
| JP2011520831A (ja) * | 2008-05-13 | 2011-07-21 | ノバルティス アーゲー | ３，５−ジアミノ−６−クロロ−ピラジン−２−カルボン酸誘導体および気道疾患処置用上皮性ナトリウムチャネルブロッカーとしてのその使用 |
| KR20110040818A (ko) | 2008-06-10 | 2011-04-20 | 노파르티스 아게 | 상피 나트륨 채널 차단제로서의 피라진 유도체 |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| US9050339B2 (en) | 2010-09-17 | 2015-06-09 | Novartis Ag | Pyrazine derivatives as ENaC blockers |
| PL2723176T3 (pl) | 2011-06-27 | 2018-01-31 | Parion Sciences Inc | Chemicznie i metabolicznie stabilny dipeptyd o silnej aktywności blokera kanału sodowego |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| HRP20171614T1 (hr) * | 2011-11-02 | 2017-12-01 | Boehringer Ingelheim International Gmbh | Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju |
| CN104024231A (zh) | 2011-11-02 | 2014-09-03 | 勃林格殷格翰国际有限公司 | 制备酰基胍和酰基硫脲化合物的新方法 |
-
2012
- 2012-10-29 HR HRP20171614TT patent/HRP20171614T1/hr unknown
- 2012-10-29 EP EP12777930.4A patent/EP2773633B1/en active Active
- 2012-10-29 MX MX2014005166A patent/MX348522B/es active IP Right Grant
- 2012-10-29 HU HUE12777930A patent/HUE034929T2/en unknown
- 2012-10-29 AP AP2014007670A patent/AP2014007670A0/xx unknown
- 2012-10-29 KR KR1020147012186A patent/KR102006612B1/ko not_active Expired - Fee Related
- 2012-10-29 UA UAA201405764A patent/UA115868C2/uk unknown
- 2012-10-29 ME MEP-2017-247A patent/ME02905B/me unknown
- 2012-10-29 DK DK12777930.4T patent/DK2773633T3/da active
- 2012-10-29 PH PH1/2014/500970A patent/PH12014500970B1/en unknown
- 2012-10-29 AU AU2012331274A patent/AU2012331274B2/en not_active Ceased
- 2012-10-29 PT PT127779304T patent/PT2773633T/pt unknown
- 2012-10-29 CN CN201280065806.8A patent/CN104024244B/zh active Active
- 2012-10-29 NO NO12777930A patent/NO2773633T3/no unknown
- 2012-10-29 SI SI201231100T patent/SI2773633T1/sl unknown
- 2012-10-29 BR BR112014010583A patent/BR112014010583A2/pt active Search and Examination
- 2012-10-29 LT LTEP12777930.4T patent/LT2773633T/lt unknown
- 2012-10-29 JP JP2014539297A patent/JP6091513B2/ja active Active
- 2012-10-29 SG SG11201401907TA patent/SG11201401907TA/en unknown
- 2012-10-29 CA CA2854217A patent/CA2854217C/en not_active Expired - Fee Related
- 2012-10-29 ES ES12777930.4T patent/ES2645744T3/es active Active
- 2012-10-29 GE GEAP201813485A patent/GEAP201813485A/en unknown
- 2012-10-29 CN CN201610685839.2A patent/CN106279110B/zh active Active
- 2012-10-29 US US13/662,791 patent/US8759349B2/en active Active
- 2012-10-29 GE GEAP201213485A patent/GEP20186880B/en unknown
- 2012-10-29 WO PCT/EP2012/071352 patent/WO2013064450A1/en not_active Ceased
- 2012-10-29 RS RS20171069A patent/RS56498B1/sr unknown
- 2012-10-29 EA EA201400521A patent/EA025158B9/ru not_active IP Right Cessation
- 2012-10-29 PE PE2014000641A patent/PE20141607A1/es active IP Right Grant
- 2012-10-29 PL PL12777930T patent/PL2773633T3/pl unknown
-
2014
- 2014-04-09 IL IL232035A patent/IL232035A/en not_active IP Right Cessation
- 2014-04-24 CL CL2014001047A patent/CL2014001047A1/es unknown
- 2014-04-28 US US14/263,344 patent/US20140228374A1/en not_active Abandoned
- 2014-04-28 TN TNP2014000180A patent/TN2014000180A1/en unknown
- 2014-04-30 CO CO14092699A patent/CO6940429A2/es unknown
- 2014-05-26 EC ECIEPI20141929A patent/ECSP14001929A/es unknown
-
2015
- 2015-08-05 US US14/818,478 patent/US9920035B2/en active Active
-
2017
- 2017-10-30 CY CY171101128T patent/CY1120974T1/el unknown
- 2017-12-13 US US15/840,309 patent/US20180194747A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6072920B2 (ja) | 複素環化合物、前記化合物を含む薬物、これらの使用及びこれらの調製方法 | |
| JP6110872B2 (ja) | ヘテロ環式化合物、前記化合物を含む薬物、その使用及びその調製方法 | |
| JP2014534222A (ja) | 複素環化合物、前記化合物を含む薬物、これらの使用及びこれらの調製方法 | |
| JP2013545790A (ja) | 医薬としての二環系置換スルホンアミド官能化フェノール | |
| JP6204977B2 (ja) | 三級アミン、前記アミンを含む薬物、その使用及びその調製方法 | |
| JP6449870B2 (ja) | 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物 | |
| HK1232876A1 (en) | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | |
| HK1196819B (en) | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | |
| OA16887A (en) | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof. | |
| NZ622469B2 (en) | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151029 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151029 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160526 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160606 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160905 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161206 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170116 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170207 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6091513 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |